May. 6 at 2:02 PM
$CYTK
Price target raised — but has the market fully priced it in?
RBC Capital lifted its PT to
$119 from
$101 while reiterating an Outperform rating.
The key driver is not just earnings, but a commercialization inflection. Myqorzo’s growth in oHCM and strong new patient starts are seen as underappreciated in the U.S. peak opportunity.
At the same time, ACACIA’s long-term potential in nHCM is highlighted, with ~
$1.3B in estimated sales by 2035.
As the company shifts from clinical to commercial stage, combined with M&A optionality, a broader re-rating could emerge.
Free sharing and subscription 👉 @StockMacroView.
